

Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/B379C6AFC692EN.html>

Date: March 2022

Pages: 116

Price: US\$ 2,000.00 (Single User License)

ID: B379C6AFC692EN

Abstracts

Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Burns - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Burns (Dermatology) pipeline landscape.

A burn is damage to body's tissues caused by heat, chemicals, electricity, sunlight or radiation. Symptoms include pain, increasing with each degree of burn, red and swollen skin, blisters and charred and blackened skin. Treatment includes antibiotics and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Burns - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Burns (Dermatology) pipeline guide also reviews of key players involved in

therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 3, 8, 1, 24, 11 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Burns (Dermatology).

The pipeline guide reviews pipeline therapeutics for Burns (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Burns (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Burns (Dermatology) therapeutics based on

mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Burns (Dermatology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Burns (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Burns (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Burns - Overview
- Burns - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Burns - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Burns - Companies Involved in Therapeutics Development
- Adial Pharmaceuticals Inc
- Aegle Therapeutics Corp
- AlgiPharma AS
- Alliance Pharma Plc
- Alloksys Life Sciences BV
- Amniotics AB
- Anterogen Co Ltd
- Bioharmony Therapeutics Inc
- Biomendics LLC
- CFM Pharma Holding BV
- Chrysalis BioTherapeutics Inc
- Claritas Pharmaceuticals Inc
- Clene Inc
- cStem Regeneration Pharmaceutical Co Ltd
- Energenesis Biomedical Co Ltd
- FirstString Research Inc
- FortuneRock (China) Ltd
- GNT Pharma Co Ltd
- Hunan Sanqing Pharmaceutical Co Ltd
- Hypo-Stream Ltd
- Imagine Pharma LLC
- Jupiter Wellness Inc

Kala Pharmaceuticals Inc
Madam Therapeutics BV
Marizyme Inc
Maxwell Biosciences Inc
MediWound Ltd
MicroCures Inc
NeoMatrix Therapeutics Inc
NextPhase Therapeutics
Oxacell AG
Phagelux Inc
Pharmaxis Ltd
QBiotics Group Ltd
Recce Pharmaceuticals Ltd
Regeneus Ltd
Rejuvenation Technologies Inc
Riptide Bioscience Inc
Se-cure Pharmaceuticals Ltd
Shulov Innovative Science Ltd
Stemsynergy Therapeutics Inc
TGV-Inhalonix Inc
Theragnostic Technologies Inc
TreeFrog Therapeutics SAS
USV Pvt Ltd
viDA Therapeutics Inc
Washburn Therapeutics Inc
Burns - Drug Profiles
(aspartame + cannabidiol) - Drug Profile
Product Description
Mechanism Of Action
History of Events
(cerium nitrate hexahydrate + silver sulfadiazine) - Drug Profile
Product Description
Mechanism Of Action
History of Events
aCT11 - Drug Profile
Product Description
Mechanism Of Action
History of Events
AGLE-102 - Drug Profile

Product Description
Mechanism Of Action
History of Events
ASCP-04 - Drug Profile
Product Description
Mechanism Of Action
aspoxicillin - Drug Profile
Product Description
Mechanism Of Action
BH-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
BH-02 - Drug Profile
Product Description
Mechanism Of Action
Biologic for Burns and Bone Fractures - Drug Profile
Product Description
Mechanism Of Action
bRESCAP - Drug Profile
Product Description
Mechanism Of Action
bromelains - Drug Profile
Product Description
Mechanism Of Action
History of Events
Burns - Drug Profile
Product Description
Mechanism Of Action
Cell Therapy to Activate TERT for Burns and Trauma - Drug Profile
Product Description
Mechanism Of Action
CNMAGZN-17 - Drug Profile
Product Description
Mechanism Of Action
Cutistem - Drug Profile
Product Description
Mechanism Of Action
EBC-1013 - Drug Profile

Product Description
Mechanism Of Action
ENERGIF-711 - Drug Profile
Product Description
Mechanism Of Action
epidermal growth factor biosimilar - Drug Profile
Product Description
Mechanism Of Action
Granexin - Drug Profile
Product Description
Mechanism Of Action
History of Events
ISN-001 - Drug Profile
Product Description
Mechanism Of Action
History of Events
KPI-012 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MB-101 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Monoclonal Antibody Conjugate to Inhibit TNF-Alpha for Burns, Inflammation and Wounds - Drug Profile
Product Description
Mechanism Of Action
History of Events
Mul-1867 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Neu-2000 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NMTcNP-8 - Drug Profile
Product Description

Mechanism Of Action

Oligomer G for Burn Wounds - Drug Profile

Product Description

Mechanism Of Action

P-12 - Drug Profile

Product Description

Mechanism Of Action

History of Events

PL-01SS - Drug Profile

Product Description

Mechanism Of Action

History of Events

PNV-5030 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Protein to Activate FGFR for Cardiovascular, CNS, Dermatology and Musculoskeletal

Disorders - Drug Profile

Product Description

Mechanism Of Action

PXS-6302 - Drug Profile

Product Description

Mechanism Of Action

History of Events

pyrvinium pamoate - Drug Profile

Product Description

Mechanism Of Action

History of Events

R-107 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RECCE-327 - Drug Profile

Product Description

Mechanism Of Action

History of Events

RP-557 - Drug Profile

Product Description

Mechanism Of Action

History of Events

rusalotide acetate - Drug Profile

Product Description

Mechanism Of Action

History of Events

SC-106 - Drug Profile

Product Description

Mechanism Of Action

SFR-9X0125 - Drug Profile

Product Description

Mechanism Of Action

siFi-2 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule for Burns - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Burns and Chronic Wounds - Drug Profile

Product Description

Mechanism Of Action

History of Events

sodium hypochlorite - Drug Profile

Product Description

Mechanism Of Action

History of Events

Stem Cell Therapy for Burns and Dermatitis - Drug Profile

Product Description

Mechanism Of Action

Stem Cell Therapy for Skin Disorders - Drug Profile

Product Description

Mechanism Of Action

Sygenus - Drug Profile

Product Description

Mechanism Of Action

Tolasure - Drug Profile

Product Description

Mechanism Of Action

TOP-3 - Drug Profile

Product Description

Mechanism Of Action

Vanadis-02 - Drug Profile

Product Description

Mechanism Of Action

VTI-1002 - Drug Profile

Product Description

Mechanism Of Action

ZEP-3 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Burns - Dormant Projects

Burns - Discontinued Products

Burns - Product Development Milestones

Featured News & Press Releases

Feb 17, 2022: MediWound awarded a U.S. Department of Defense research grant for the development of NexoBrid for the U.S. Army

Feb 10, 2022: MediWound announces additional \$9 million in funding from BARDA to support Nexobrid BLA resubmission and the expanded access treatment protocol

Nov 18, 2021: EMA provides regulatory path for pediatric label extension for NexoBrid

Nov 16, 2021: Jupiter Wellness announces JW-300 clinical trial results

Oct 21, 2021: Achievement of the primary endpoint from the Phase III study in Japan of KMW-1 presented at the 47th Annual Meeting of the Japanese Society for Burn Injuries

Oct 19, 2021: Jupiter Wellness announces first patient dosing for double-blinded placebo controlled trial of JW-300 for the treatment of first degree burns

Aug 31, 2021: Pharmaxis treatment to prevent wound and burns scars clears phase 1 trial

Jul 20, 2021: MediWound announces positive topline results from phase 3 pediatric study (CIDS) of NexoBrid for eschar removal of severe thermal burns

Jun 29, 2021: MediWound receives complete response letter from U.S. FDA for NexoBrid biologics license application

Jun 28, 2021: Kaken has filed an application in Japan for Regulatory Approval of KMW-1

Apr 01, 2021: Pharmaxis to start world-first trial of scar-reducing wound treatment

Dec 14, 2020: MediWound continues global expansion with distribution agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group

Oct 28, 2020: MediWound completes enrollment stage of its Nexobrid phase 3 pediatric study

Oct 09, 2020: Vericel to host virtual analyst and investor day on October 16, 2020

Oct 08, 2020: Aegle Therapeutics announces award of grant by U.S. Department of Defense's ('DoD') congressionally directed medical research programs ('CDMRP') for development of AGLE-102

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Burns, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Burns - Pipeline by Adial Pharmaceuticals Inc, 2022
Burns - Pipeline by Aegle Therapeutics Corp, 2022
Burns - Pipeline by AlgiPharma AS, 2022
Burns - Pipeline by Alliance Pharma Plc, 2022
Burns - Pipeline by Alloksys Life Sciences BV, 2022
Burns - Pipeline by Amniotics AB, 2022
Burns - Pipeline by Anterogen Co Ltd, 2022
Burns - Pipeline by Bioharmony Therapeutics Inc, 2022
Burns - Pipeline by Biomendics LLC, 2022
Burns - Pipeline by CFM Pharma Holding BV, 2022
Burns - Pipeline by Chrysalis BioTherapeutics Inc, 2022
Burns - Pipeline by Claritas Pharmaceuticals Inc, 2022
Burns - Pipeline by Clene Inc, 2022
Burns - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2022
Burns - Pipeline by Energenesis Biomedical Co Ltd, 2022
Burns - Pipeline by FirstString Research Inc, 2022
Burns - Pipeline by FortuneRock (China) Ltd, 2022
Burns - Pipeline by GNT Pharma Co Ltd, 2022
Burns - Pipeline by Hunan Sanqing Pharmaceutical Co Ltd, 2022
Burns - Pipeline by Hypo-Stream Ltd, 2022
Burns - Pipeline by Imagine Pharma LLC, 2022
Burns - Pipeline by Jupiter Wellness Inc, 2022

Burns - Pipeline by Kala Pharmaceuticals Inc, 2022
Burns - Pipeline by Madam Therapeutics BV, 2022
Burns - Pipeline by Marizyme Inc, 2022
Burns - Pipeline by Maxwell Biosciences Inc, 2022
Burns - Pipeline by MediWound Ltd, 2022
Burns - Pipeline by MicroCures Inc, 2022
Burns - Pipeline by NeoMatrix Therapeutics Inc, 2022
Burns - Pipeline by NextPhase Therapeutics, 2022
Burns - Pipeline by Oxacell AG, 2022
Burns - Pipeline by Phagelux Inc, 2022
Burns - Pipeline by Pharmaxis Ltd, 2022
Burns - Pipeline by QBiotics Group Ltd, 2022
Burns - Pipeline by Recce Pharmaceuticals Ltd, 2022
Burns - Pipeline by Regeneus Ltd, 2022
Burns - Pipeline by Rejuvenation Technologies Inc, 2022
Burns - Pipeline by Riptide Bioscience Inc, 2022
Burns - Pipeline by Se-cure Pharmaceuticals Ltd, 2022
Burns - Pipeline by Shulov Innovative Science Ltd, 2022
Burns - Pipeline by Stemsynergy Therapeutics Inc, 2022
Burns - Pipeline by TGV-Inhalonix Inc, 2022
Burns - Pipeline by Theragnostic Technologies Inc, 2022
Burns - Pipeline by TreeFrog Therapeutics SAS, 2022
Burns - Pipeline by USV Pvt Ltd, 2022
Burns - Pipeline by viDA Therapeutics Inc, 2022
Burns - Pipeline by Washburn Therapeutics Inc, 2022
Burns - Dormant Projects, 2022
Burns - Dormant Projects, 2022 (Contd..1)
Burns - Dormant Projects, 2022 (Contd..2)
Burns - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

- Number of Products under Development for Burns, 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Burns Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/B379C6AFC692EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B379C6AFC692EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

